Search
Recursion Pharmaceuticals Inc
RXRXAdd to Watchlist
3.000USD
+0.030+1.02%
Close 07-29 16:00（ET）Quotes delayed by 15 min
1.58BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-29The current earnings forecast score of Recursion Pharmaceuticals Inc is 6.75, ranking 323 out of 384 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 10.00 and a low of 3.00.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
6.700
Target Price
+122.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Recursion Pharmaceuticals Inc
RXRX
7
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Recursion Pharmaceuticals Inc's expected revenue for the next quarter?
Recursion Pharmaceuticals Inc's expected revenue is 11.95M.
What is Recursion Pharmaceuticals Inc's price target?
Analysts forecast that Recursion Pharmaceuticals Inc's price target is USD 6.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 3.00.
How have Recursion Pharmaceuticals IncRXRX's recent earnings per share performed?
The market expectation was USD -0.22, while Recursion Pharmaceuticals IncRXRX's earnings per share (EPS) for the previous quarter was USD -0.21. EPS for the next quarter is expected at USD -0.23.
What is the analyst rating for Recursion Pharmaceuticals Inc?
Based on the ratings of Recursion Pharmaceuticals Inc's stock from 7 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.